NCT02360397View on ClinicalTrials.gov

Ranolazine Mediated PVC Reduction in Ischemic Heart Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

February 23, 2018

Conditions

Ventricular Premature ComplexesMyocardial Ischemia

Interventions

DRUG

ranolazine

Ranolazine 1000 mg tablet twice daily for 30 days

Trial Locations (1)

02886

Kent Hospital, Warwick

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Kent Hospital, Rhode Island

OTHER

NCT02360397 - Ranolazine Mediated PVC Reduction in Ischemic Heart Disease | Biotech Hunter | Biotech Hunter